drugset / Trial / NCT00372489

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

NCT00372489

Phase 2 Terminated 81 enrolled Affymax
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the long term safety and tolerability of peginesatide for the maintenance of hemoglobin in participants with chronic kidney disease (CKD) who had received at least 24 weeks of peginesatide treatment in an earlier study.

Timeline

Start
2006-09
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject peginesatide Peptide 0.087 mg/kg Intravenous